Original ArticlesComparison of Estimates of Insulin Sensitivity in Pre- and Postmenopausal Women Using the Insulin Tolerance Test and the Frequently Sampled Intravenous Glucose Tolerance Test

OBJECTIVE: We assessed insulin sensitivity in women comparing the insulin tolerance test (ITT) with the intravenous glucose tolerance test with frequent sampling and computer modeling (FSIVGTT) and evaluated the effects ofhormonal therapy in postmenopausal women using both methods. METHODS: This prospective study tested 18 premenopausal women and ten postmenopausal women randomized to receive either estrogen alone or estrogen with a sequential progestin for 6 months at a menopause research clinic. All subjects received an ITT and an FSIVGTT within 48-72 hours of each other in random sequence. Postmenopausal women were then randomized to receive either 0.625 mg conjugated equine estrogen for 6 months or 0.625 mg conjugated equine estrogen with medroxyprogesterone acetate, 10 mg, for 10 days each month for 6 months. Both the ITT and the FSIVGTT were repeated following hormonal therapy at 2 and 6 months. Plasma insulin and glucose were measured; insulin sensitivity was calculated after the ITT (Kitt) and the FSIVGTT (Si) at each visit in each group. RESULTS: A close correlation was found between Kitt and Si values at initial testing in both pre- and postmenopausal women and following both types of hormonal therapy (r = 0.76 for all tests, P < .001). A reduction in insulin sensitivity was observed in postmenopausal compared to premenopausal women; this occurred in five of ten postmenopausal women using the Kitt mea surement and in four often women using Si. Estrogen replacement had a beneficial effect on insulin sensitivity. While Kitt increased by 24.2 ± 9.6% (P < .05), the increase in Si (6.7 ± 18%) was not significant because of the variability with this measurement. An attenuation in insulin sensi tivity was seen with added progestin. Kitt values decreased by 17.7 ± 7.7% and Si values by 31.9 ± 12%. Similar findings were noted at 2 and 6 months. CONCLUSIONS: The ITT and FSIVG TT provide quantitatively similar information regard ing insulin sensitivity in healthy women. A mild degree of insulin resistance appears to be present in some healthy postmenopausal women. Estrogen appears to improve insulin sensitivity, while added progestin may attenuate this beneficial effect. (J Soc Gynecol Invest 1994;1:150-4)

[1]  J. Haapakoski,et al.  Plasma insulin as coronary heart disease risk factor: relationship to other risk factors and predictive value during 9 1/2-year follow-up of the Helsinki Policemen Study population. , 2009, Acta medica Scandinavica. Supplementum.

[2]  R. Lobo,et al.  The route of administration influences the effect of estrogen on insulin sensitivity in postmenopausal women. , 1994, Fertility and sterility.

[3]  R. Lobo,et al.  A possible bimodal effect of estrogen on insulin sensitivity in postmenopausal women and the attenuating effect of added progestin. , 1993, Fertility and sterility.

[4]  I. Godsland,et al.  Insulin resistance, secretion, and elimination in postmenopausal women receiving oral or transdermal hormone replacement therapy. , 1993, Metabolism: clinical and experimental.

[5]  M. Pike,et al.  A reevaluation of estrogen status in postmenopausal women who smoke. , 1992, American journal of obstetrics and gynecology.

[6]  R. Lobo,et al.  Clinical review 27: Effects of hormonal replacement on lipids and lipoproteins in postmenopausal women. , 1991, The Journal of clinical endocrinology and metabolism.

[7]  B. Henderson,et al.  Decreased Mortality in Users of Estrogen Replacement Therapy , 1991, Archives of internal medicine.

[8]  M. Laakso,et al.  Ischemic heart disease risk in postmenopausal women. Effects of estrogen use on glucose and insulin levels. , 1990, Arteriosclerosis.

[9]  L. T. Hunt,et al.  Selective inhibition of protein disulfide isomerase by estrogens. , 1989, The Journal of biological chemistry.

[10]  C. Zancanaro,et al.  Estimates of in vivo insulin action in man: comparison of insulin tolerance tests with euglycemic and hyperglycemic glucose clamp studies. , 1989, The Journal of clinical endocrinology and metabolism.

[11]  R N Bergman,et al.  Equivalence of the insulin sensitivity index in man derived by the minimal model method and the euglycemic glucose clamp. , 1987, The Journal of clinical investigation.

[12]  R N Bergman,et al.  The Insulin Sensitivity Index in Nondiabetic Man: Correlation Between Clamp-derived and IVGTT-derived Values , 1986, Diabetes.

[13]  B Rosner,et al.  A prospective study of postmenopausal estrogen therapy and coronary heart disease. , 1985, The New England journal of medicine.

[14]  F. Khan-dawood,et al.  The effect of sex steroids on insulin binding by target tissues in the rat. , 1983, Contraception.

[15]  W. Spellacy,et al.  The effects of two years of mestranol treatment on carbohydrate metabolism. , 1982, Metabolism: clinical and experimental.

[16]  R. Bergman,et al.  Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and beta-cell glucose sensitivity from the response to intravenous glucose. , 1981, The Journal of clinical investigation.

[17]  P. McNamara,et al.  Morbidity and Mortality in Diabetics In the Framingham Population: Sixteen Year Follow-up Study , 1974, Diabetes.

[18]  P. Trinder,et al.  Determination of blood glucose using 4-amino phenazone as oxygen acceptor. , 1969, Journal of clinical pathology.

[19]  E. Barrett-Connor,et al.  Noncontraceptive estrogen use and cardiovascular disease. , 1985, Epidemiologic reviews.

[20]  P Ducimetière,et al.  Coronary heart disease mortality in relation with diabetes, blood glucose and plasma insulin levels. The Paris Prospective Study, ten years later. , 1985, Hormone and metabolic research. Supplement series.

[21]  A. Behl,et al.  Diabetes and coronary heart disease. , 1968, The Journal of the Association of Physicians of India.